Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) – Pipeline Review, H2 2016 – Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Industries

The Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) – Pipeline Review, H2 2016 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Markets.

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) – Pipeline Review, H2 2016

Summary

‘Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) – Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
– The report reviews Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
– The report assesses Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read more and order at Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) – Pipeline Review, H2 2016

ADHD Therapeutics to 2020 – Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations – Drugs by Therapeutic Area, Mental Disorders Drugs, Pharmaceuticals Industries

The ADHD Therapeutics to 2020 – Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Mental Disorders Drugs, Pharmaceuticals Markets.

Changes in diagnostic criteria have reduced the symptom threshold for diagnosis and finally bring the acceptance of adult ADHD to the clinical setting, enabling those previously unable to obtain a diagnosis to be diagnosed for ADHD treatment. In the case of adult ADHD, 4.1% of US adults are believed to suffer from ADHD, 41.3% of these cases are classified as severe and would be eligible for therapeutic intervention.

The current ADHD therapeutics market is flooded with generics and dominated by the use of Extended-Release (ER) stimulant drugs which have superseded short-acting, Immediate-Release (IR) formulations. With dose titration per patient, ER stimulants are usually effective in 70-90% of patients. However, all stimulants apart from Vyvanse come with potential for abuse. Non-stimulants are used for those who are poor-responders, have poor cardiac history or prefer non-stimulant medication however their efficacy is lacking in comparison. Currently, 10% of adult patients are using a combination of ER and IR treatment for an additional duration, representing an unmet need within this growing ADHD segment.

The current developmental pipeline addresses these gaps in the market, with three potential non-stimulants entering the market during the forecast period and SHP465, which aims to address the unmet need in the adult ADHD segment with its tailored duration of action. In spite of anticipated drug approvals, patents expirations and increased generic competition will cause ACoT to remain fairly static and even decrease across some nations.

As a result, the global market is not expected to be driven by drug approvals, but primarily by a growing prevalence, increase in rates of diagnosis, and therefore eligible treatment population. Global market revenues are forecast to rise at a CAGR of 4.8% to $9.4 billion by 2020.

Scope:

The report analyzes the incidence of ADHD, current options for its treatment, pipeline, market forecasts and deals surrounding ADHD therapeutics.The report covers and includes –
– A brief introduction into ADHD, symptoms, diagnosis, epidemiology, etiology, pathophysiology, economic implications of their treatment and the current treatment options for the condition.
– An analysis of the currently marketed ADHD drugs, including recent sales figures, safety and efficacy data of the drugs and a discussion of the likely performance of each drug within the forecast period.
– Comprehensive reviews of the pipeline for ADHD drugs, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type and mechanism of action.
– Additional statistical analysis of clinical trial duration, size and attrition rate by phase and mechanism of action.
– An in-depth, multi-scenario forecast model for the ADHD drugs market in the US, Canada, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated performance of both marketed drugs and any expected to be approved within the forecast period, and takes into account drug cost, patent expiration, efficacy, safety and likely prescription volumes.
– A detailed discussion of drivers and barriers for the ADHD market
– An in-depth analysis of licensing and co-development deals involving drugs indicated in ADHD, including an in-depth outline of key deals.

Reasons to purchase:

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to –
– Understand the key signaling pathways and molecular targets currently under investigation in drug development for ADHD.
– Gain an in-depth view of the current status of the ADHD therapeutics pipeline, including the most common molecule types and molecular targets in development.
– Observe trends in clinical trial duration and size amongst clinical phases and mechanisms of action, and use the clinical trial attrition rate analysis to assess the risk profiles of current and/or future developmental programs for ADHD therapeutics.
– Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ADHD therapeutics market.
– Analyze current and past deals surrounding ADHD therapeutics, including their value, year of deal and in-depth details of key deals within the ADHD market.

Read more and order at ADHD Therapeutics to 2020 – Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

Italy Respiratory Diseases: Supplier Shares and Country Segment Forecasts 2017-2021 – Drugs by Therapeutic Area, Pharmaceuticals, Respiratory Drugs Industries

The Italy Respiratory Diseases: Supplier Shares and Country Segment Forecasts 2017-2021 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Pharmaceuticals, Respiratory Drugs Markets.

About This Report

This new 281-page report presents detailed analysis of the Italian Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs.

In addition to market share and sales forecasts, the report:

– Examines market applications of Molecular Diagnostics,
Monoclonal Antibodies, Immunoassays, IT and other emerging technologies;

– Reviews features and operating characteristics of major analyzers used
for microbiology testing;

– Profiles key suppliers and potential market entrants developing innovative
technologies and products; and

– Analyzes emerging opportunities, alternative market penetration strategies,
market entry barriers/risks, and strategic planning issues.

Methodology

The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products.

In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as proprietary data files was conducted.

Contains 281 pages and 21 tables

Read more and order at Italy Respiratory Diseases: Supplier Shares and Country Segment Forecasts 2017-2021

The 2018-2023 World Outlook for Artificial Tears – Drugs by Therapeutic Area, Optical Disorders Drugs, Pharmaceuticals Industries

The The 2018-2023 World Outlook for Artificial Tears Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Optical Disorders Drugs, Pharmaceuticals Markets.

This study covers the world outlook for artificial tears across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E., for artificial tears. It also shows how the P.I.E. is divided across the world's regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

1.3 The Methodology

In order to estimate the latent demand for artificial tears on a worldwide basis, I used a multi-stage approach. Before applying the approach, one needs a basic theory from which such estimates are created. In this case, I heavily rely on the use of certain basic economic assumptions. In particular, there is an assumption governing the shape and type of aggregate latent demand functions. Latent demand functions relate the income of a country, city, state, household, or individual to realized consumption. Latent demand (often realized as consumption when an industry is efficient), at any level of the value chain, takes place if an equilibrium is realized. For firms to serve a market, they must perceive a latent demand and be able to serve that demand at a minimal return. The single most important variable determining consumption, assuming latent demand exists, is income (or other financial resources at higher levels of the value chain). Other factors that can pivot or shape demand curves include external or exogenous shocks (i.e., business cycles), and or changes in utility for the product in question.

Ignoring, for the moment, exogenous shocks and variations in utility across countries, the aggregate relation between income and consumption has been a central theme in economics. The figure below concisely summarizes one aspect of problem. In the 1930s, John Meynard Keynes conjectured that as incomes rise, the average propensity to consume would fall. The average propensity to consume is the level of consumption divided by the level of income, or the slope of the line from the origin to the consumption function. He estimated this relationship empirically and found it to be true in the short-run (mostly based on cross-sectional data). The higher the income, the lower the average propensity to consume. This type of consumption function is shown as "B" in the figure below (note the rather flat slope of the curve). In the 1940s, another macroeconomist, Simon Kuznets, estimated long-run consumption functions which indicated that the marginal propensity to consume was rather constant (using time series data across countries). This type of consumption function is show as "B" in the figure below (note the higher slope and zero-zero intercept).

The average propensity to consume is constant. For a general overview of this subject area, see Principles of Macroeconomics by N. Gregory Mankiw, South-Western College Publishing; ISBN: 0030340594; 2nd edition (February 2002).

Is it declining or is it constant? A number of other economists, notably Franco Modigliani and Milton Friedman, in the 1950s (and Irving Fisher earlier), explained why the two functions were different using various assumptions on intertemporal budget constraints, savings, and wealth. The shorter the time horizon, the more consumption can depend on wealth (earned in previous years) and business cycles. In the long-run, however, the propensity to consume is more constant. Similarly, in the long-run, households, industries, or countries with no income eventually have no consumption (wealth is depleted). While the debate surrounding beliefs about how income and consumption are related and interesting, in this study a very particular school of thought is adopted. In particular, we are considering the latent demand for artificial tears across some 190 countries. The smallest have fewer than 10,000 inhabitants. I assume that all of these counties fall along a "long-run" aggregate consumption function. This long-run function applies despite some of these countries having wealth; current income dominates the latent demand for artificial tears. So, latent demand in the long-run has a zero intercept. However, I allow firms to have different propensities to consume (including being on consumption functions with differing slopes, which can account for differences in industrial organization, and end-user preferences).

Given this overriding philosophy, I will now describe the methodology used to create the latent demand estimates for artificial tears. Since this methodology applies to a large number of categories, the rather academic discussion below is general and can be applied to a wide variety of categories, not just artificial tears.

1.3.1 Step 1. Product Definition And Data Collection

Any study of latent demand across countries requires that some standard be established to define "efficiently served". Having implemented various alternatives and matched these with market outcomes, I have found that the optimal approach is to assume that certain key countries are more likely to be at or near efficiency than others. These countries are given greater weight than others in the estimation of latent demand compared to other countries for which no known data are available. Of the many alternatives, I have found the assumption that the world’s highest aggregate income and highest income-per-capita markets reflect the best standards for “efficiency”. High aggregate income alone is not sufficient (i.e., China has high aggregate income, but low income per capita and cannot be assumed to be efficient). Aggregate income can be operationalized in a number of ways, including gross domestic product (for industrial categories), or total disposable income (for household categories; population times average income per capita, or number of households times average household income per capita). Brunei, Nauru, Kuwait, and Lichtenstein are examples of countries with high income per capita, but not assumed to be efficient, given low aggregate level of income (or gross domestic product); these countries have, however, high incomes per capita but may not benefit from the efficiencies derived from economies of scale associated with large economies. Only countries with high income per capita and large aggregate income are assumed efficient. This greatly restricts the pool of countries to those in the OECD (Organization for Economic Cooperation and Development), like the United States, or the United Kingdom (which were earlier than other large OECD economies to liberalize their markets).

The selection of countries is further reduced by the fact that not all countries in the OECD report have industry revenues at the category level. Countries that typically have ample data at the aggregate level that meet the efficiency criteria include the United States, the United Kingdom, and in some cases France and Germany.
Is it declining or is it constant? A number of other economists, notably Franco Modigliani and Milton Friedman, in the 1950s (and Irving Fisher earlier), explained why the two functions were different using various assumptions on intertemporal budget constraints, savings, and wealth. The shorter the time horizon, the more consumption can depend on wealth (earned in previous years) and business cycles. In the long-run, however, the propensity to consume is more constant. Similarly, in the long-run, households, industries, or countries with no income eventually have no consumption (wealth is depleted). While the debate surrounding beliefs about how income and consumption are related and interesting, in this study a very particular school of thought is adopted. In particular, we are considering the latent demand for artificial tears across some 190 countries. The smallest have fewer than 10,000 inhabitants. I assume that all of these counties fall along a "long-run" aggregate consumption function. This long-run function applies despite some of these countries having wealth; current income dominates the latent demand for artificial tears. So, latent demand in the long-run has a zero intercept. However, I allow firms to have different propensities to consume (including being on consumption functions with differing slopes, which can account for differences in industrial organization, and end-user preferences).Given this overriding philosophy, I will now describe the methodology used to create the latent demand estimates for artificial tears. Since this methodology applies to a large number of categories, the rather academic discussion below is general and can be applied to a wide variety of categories, not just artificial tears.

1.3.1 Step 1. Product Definition And Data Collection

Any study of latent demand across countries requires that some standard be established to define "efficiently served". Having implemented various alternatives and matched these with market outcomes, I have found that the optimal approach is to assume that certain key countries are more likely to be at or near efficiency than others. These countries are given greater weight than others in the estimation of latent demand compared to other countries for which no known data are available. Of the many alternatives, I have found the assumption that the world’s highest aggregate income and highest income-per-capita markets reflect the best standards for “efficiency”. High aggregate income alone is not sufficient (i.e., China has high aggregate income, but low income per capita and cannot be assumed to be efficient). Aggregate income can be operationalized in a number of ways, including gross domestic product (for industrial categories), or total disposable income (for household categories; population times average income per capita, or number of households times average household income per capita). Brunei, Nauru, Kuwait, and Lichtenstein are examples of countries with high income per capita, but not assumed to be efficient, given low aggregate level of income (or gross domestic product); these countries have, however, high incomes per capita but may not benefit from the efficiencies derived from economies of scale associated with large economies. Only countries with high income per capita and large aggregate income are assumed efficient. This greatly restricts the pool of countries to those in the OECD (Organization for Economic Cooperation and Development), like the United States, or the United Kingdom (which were earlier than other large OECD economies to liberalize their markets).The selection of countries is further reduced by the fact that not all countries in the OECD report have industry revenues at the category level. Countries that typically have ample data at the aggregate level that meet the efficiency criteria include the United States, the United Kingdom, and in some cases France and Germany.Latent demand is therefore estimated using data collected for relatively efficient markets from independent data sources (e.g. Euromonitor, Mintel, Thomson Financial Services, the U.S. Industrial Outlook, the World Resources Institute, the Organization for Economic Cooperation and Development, various agencies from the United Nations, industry trade associations, the International Monetary Fund, and the World Bank). Depending on original data sources used, the definition of "artificial tears" is established. In the case of this report, the data were reported at the aggregate level, with no further breakdown or definition. In other words, any potential products that might be incorporated within artificial tears fall under this category. Public sources rarely report data at the disaggregated level in order to protect private information from individual firms that might dominate a specific product-market. These sources will therefore aggregate across components of a category and report only the aggregate to the public. While private data are certainly available, this report only relies on public data at the aggregate level without reliance on the summation of various category components. In other words, this report does not aggregate a number of components to arrive at the "whole". Rather, it starts with the "whole", and estimates the whole for all countries and the world at large (without needing to know the specific parts that went into the whole in the first place).Given this caveat, in this report we define the sales of artificial tears as including all commonly understood products falling within this broad category, such as over-the-counter (OTC) products designed to give temporary relief from dry eye syndrome (DES) symptoms, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Novartis, Johnson & Johnson, Allergan, Bausch & Lomb, and Akorn. In addition to the sources indicated below, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication’s release in 2017).This report was prepared from a variety of sources including excerpts from documents and official reports or databases published by the World Bank, the U.S. Department of Commerce, the U.S. State Department, various national agencies, the International Monetary Fund, the Central Intelligence Agency, various agencies from the United Nations (e.g. ILO, ITU, UNDP, etc.), and non-governmental sources and various public sources cited in the trade press.

1.3.2 Step 2. Filtering And Smoothing

Based on the aggregate view of artificial tears as defined above, data were then collected for as many similar countries as possible for that same definition, at the same level of the value chain. This generates a convenience sample of countries from which comparable figures are available. If the series in question do not reflect the same accounting period, then adjustments are made. In order to eliminate short-term effects of business cycles, the series are smoothed using a 2-year moving average weighting scheme (longer weighting schemes do not substantially change the results). If data are available for a country, but these reflect short-run aberrations due to exogenous shocks (such as would be the case of beef sales in a country stricken with foot and mouth disease), these observations were dropped or "filtered" from the analysis.

1.3.3 Step 3. Filling In Missing Values

In some cases, data are available for countries on a sporadic basis. In other cases, data from a country may be available for only one year. From a Bayesian perspective, these observations should be given the greatest weight in estimating missing years. Assuming that other factors are held constant, the missing years are extrapolated using changes and growth in aggregate national income. Based on the overriding philosophy of a long-run consumption function (defined earlier), countries which have missing data for any given year are estimated based on historical dynamics of aggregate income for that country.

1.3.4 Step 4. Varying Parameter, Non-Linear Estimation

Given the data available from the first three steps, the latent demand in additional countries is estimated using a "varying-parameter cross-sectionally pooled time series model".

The interested reader can find longer discussions of this type of modeling in Studies in Global Econometrics (Advanced Studies in Theoretical and Applied Econometrics V. 30), by Henri Theil, et al., Kluwer Academic Publishers; ISBN: 0792336607; (June 1996), and in Principles of Econometrics, by Henri Theil John Wiley & Sons; ISBN: 0471858455; (December 1971), and in Econometric Models and Economic Forecasts by Robert S. Pindyck, Daniel L. Rubinfeld McGraw Hill Text; ISBN: 0070500983; 3rd edition (December 1991). Simply stated, the effect of income on latent demand is assumed to be constant across countries unless there is empirical evidence to suggest that this effect varies (i.e., the slope of the income effect is not necessarily the same for all countries). This assumption applies across countries along the aggregate consumption function, but also over time (i.e., not all countries are perceived to have the same income growth prospects over time and this effect can vary from country to country as well). Another way of looking at this is to say that latent demand for artificial tears is more likely to be similar across countries that have similar characteristics in terms of economic development (i.e., African countries will have similar latent demand structures controlling for the income variation across the pool of African countries). This approach is useful across countries for which some notion of non-linearity exists in the aggregate cross-country consumption function. For some categories, however, the reader must realize that the numbers will reflect a country’s contribution to global latent demand and may never be realized in the form of local sales. For certain country-category combinations this will result in what at first glance will be odd results. For example, the latent demand for the category "space vehicles" will exist for Togo even though they have no space program. The assumption is that if the economies in these countries did not exist, the world aggregate for these categories would be lower. The share attributed to these countries is based on a proportion of their income (however small) being used to consume the category in question (i.e., perhaps via resellers).

1.3.5 Step 5. Fixed-Parameter Linear Estimation

Nonlinearities are assumed in cases where filtered data exist along the aggregate consumption function. Because the world consists of more than 200 countries, there will always be those countries, especially toward the bottom of the consumption function, where non-linear estimation is simply not possible. For these countries, equilibrium latent demand is assumed to be perfectly parametric and not a function of wealth (i.e., a country’s stock of income), but a function of current income (a country’s flow of income). In the long run, if a country has no current income, the latent demand for artificial tears is assumed to approach zero. The assumption is that wealth stocks fall rapidly to zero if flow income falls to zero (i.e., countries which earn low levels of income will not use their savings, in the long run, to demand artificial tears). In a graphical sense, for low-income countries, latent demand approaches zero in a parametric linear fashion with a zero-zero intercept. In this stage of the estimation procedure, low-income countries are assumed to have a latent demand proportional to their income, based on the country closest to it on the aggregate consumption function.

1.3.6 Step 6. Aggregation And Benchmarking

Based on the models described in Chapter 1, latent demand figures are estimated for all countries of the world, including for the smallest economies. These are then aggregated to get world totals and regional totals. To make the numbers more meaningful, regional and global demand averages are presented. Figures are rounded, so minor inconsistencies may exist across tables.

1.3.7 Step 7. Latent Demand Density: Allocating Across Cities

With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report also covers the world’s top 2,000 cities. The purpose is to understand the density of demand within a country and the extent to which a city might be used as a point of distribution within its region. From an economic perspective, however, a city does not represent a population within rigid geographical boundaries. To an economist or strategic planner, a city represents an area of dominant influence over markets in adjacent areas. This influence varies from one industry to another, but also from one period of time to another.

Similar to country-level data, the reader needs to realize that latent demand allocated to a city may or may not represent real sales. For many items, latent demand is clearly observable in sales, as in the case for food or housing items. Consider, again, the category "satellite launch vehicles." Clearly, there are no launch pads in most cities of the world. However, the core benefit of the vehicles (e.g. telecommunications, etc.) is "consumed" by residents or industries within the world's cities. Without certain cities, in other words, the world market for satellite launch vehicles would be lower for the world in general. One needs to allocate, therefore, a portion of the worldwide economic demand for launch vehicles to regions, countries, and cities. This report takes the broader definition and considers, therefore, a city as a part of the global market. I allocate latent demand across areas of dominant influence based on the relative economic importance of cities within its home country, within its region, and across the world total. Not all cities are estimated within each country as demand may be allocated to adjacent areas of influence. Since some cities have higher economic wealth than others within the same country, a city’s population is not generally used to allocate latent demand. Rather, the level of economic activity of the city is used vis-à-vis others.

Read more and order at The 2018-2023 World Outlook for Artificial Tears

Lexicon's LX4211 – FDA canagliflozin decision is key bellweather – Drugs by Therapeutic Area, Endocrine and Metabolic Disorders Drugs, Pharmaceuticals Industries

The Lexicon's LX4211 – FDA canagliflozin decision is key bellweather Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Endocrine and Metabolic Disorders Drugs, Pharmaceuticals Markets.

LX4211 is part of a new class of type 2 diabetes agents that inhibit the SGLT2 glucose transporter, thereby blocking reabsorption of glucose that the kidneys have excreted into the urine. However, it is distinct from its predecessors in the class in that it also inhibits SGLT1, another glucose transporter that facilitates the absorption of dietary glucose from the gut.

The regulatory pathway for a competing SGLT2 inhibitor (BMS/AZN’ dapagliflozin) has been somewhat rocky and the PDUFA for another of these agents (J&J’s canagliflozin) is eminent (March 31, 2013), which should provide important regulatory signals for LX4211 as well.

This report explores the underlying pharmacology of these agents, available clinical data, and the regulatory landscape and its risks. In doing so, it attempts to answer two basic questions: Will LX4211 gain regulatory approval and will it be able to gain market share vs competitors?

Read more and order at Lexicon's LX4211 – FDA canagliflozin decision is key bellweather

Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2016 – Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Industries

The Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2016 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Markets.

Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2016, provides an overview of the Hematopoietic Stem Cell Transplantation (Immunology) pipeline landscape.

Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV) infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. Predisposing risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Treatment includes immunosuppressive drugs.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 3 and 1 respectively for Hematopoietic Stem Cell Transplantation.

Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation (Immunology).
– The pipeline guide reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hematopoietic Stem Cell Transplantation (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hematopoietic Stem Cell Transplantation (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read more and order at Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2016

Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) – Pipeline Review, H1 2016 – Drugs by Therapeutic Area, Immune Disorders Drugs, Pharmaceuticals Industries

The Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) – Pipeline Review, H1 2016 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Immune Disorders Drugs, Pharmaceuticals Markets.

Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) – Pipeline Review, H1 2016

Summary

‘Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) – Pipeline Review, H1 2016’, provides in depth analysis on Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted pipeline therapeutics.

The report provides comprehensive information on the Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24)
– The report reviews Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
– The report assesses Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read more and order at Mitogen Activated Protein Kinase 3 (MAP Kinase 3 or Insulin-Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or ERK-1 or EC 2.7.11.24) – Pipeline Review, H1 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) – Pipeline Review, H2 2016 – Drugs by Therapeutic Area, Endocrine and Metabolic Disorders Drugs, Pharmaceuticals Industries

The Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) – Pipeline Review, H2 2016 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Endocrine and Metabolic Disorders Drugs, Pharmaceuticals Markets.

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) – Pipeline Review, H2 2016

Summary

‘Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) – Pipeline Review, H2 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3)
– The report reviews Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics and enlists all their major and minor projects
– The report assesses Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read more and order at Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) – Pipeline Review, H2 2016

Antibiotics and Antibiotic Resistance – Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals Industries

The Antibiotics and Antibiotic Resistance Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals Markets.

An all–encompassing look at different types of antibiotics and the high–priority issue of antibiotic resistance

Important weapons in the arsenal of modern medicine, antibiotics remain the greatest and most effective combatant known for fighting infectious diseases. However, recent factors spurring an increase in resistant bacteria strains pose a serious threat to the efficacy of antibiotic drugs an alarming prospect for healthcare specialists around the globe.

Separating itself from standard texts in the field that discuss antibiotics solely within the context of bacteriology and infectious diseases, Antibiotics and Antibiotic Resistance singles out antibiotics as a unique group of agents. Both concise and comprehensive, this forward–thinking guide serves as more than just a general reference on different types of antibiotics and their specific medicinal properties. It also includes an in–depth discussion of antibiotic resistance mechanisms to closely examine how they cultivate malicious bacteria that stably resist our therapeutic efforts. In addition, Antibiotics and Antibiotic Resistance:

  • Provides a wide–ranging overview of topics in antibiotics and antibiotics resistance

  • Describes molecular mechanisms of resistance and newly observed genetic principles for the spread of resistance

  • Enables readers to learn about antibiotics in a way that specifically concentrates on the importance of counteracting resistance

Filled with recent examples of efforts to find new antibacterial agents, Antibiotics and Antibiotic Resistance emerges as a valuable tool for allowing future scientists to recognize the telltale signs of antibiotic–resistant strains, while helping them to invigorate their research in the race to head off a potentially critical health crisis.

Read more and order at Antibiotics and Antibiotic Resistance

Japanese Market Report for Hyaluronic Acid Viscosupplementation – Drugs by Therapeutic Area, Immune Disorders Drugs, Pharmaceuticals Industries

The Japanese Market Report for Hyaluronic Acid Viscosupplementation Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Immune Disorders Drugs, Pharmaceuticals Markets.

Hyaluronic acids (HAs) are naturally occurring biopolymer fluids found in the joints that help cushion them from wear. Sufferers of osteoarthritis are deficient in these fluids. One of the treatment options for these patients is HA viscosupplement injections.

Viscosupplements are injectable products that come in three varieties of injection regimens. The exact mechanism of their action is unclear, but the therapy works by increasing the viscoelasticity of the synovial fluid, thereby reducing friction between the joints. The immediate short-term benefit appears to be mainly pain relief, more so than actual healing, although this does allow for long-term improvements in mobility and range of motion. The products are appropriate in cases where the patient has failed to respond to pharmacological or steroid therapy and there is no contraindication to injection therapy. The effectiveness of these products has mainly been established for the knee joints, and has not yet been very well established for use in other joints of the body.
Viscoelasticity is a property describing the ability to absorb shock. Fluids that have a high degree of this property provide greater resistance to sudden shocks and impacts than they do to loads that are applied gradually. In an osteoarthritic knee, the cartilage wears faster than it can repair itself. The shock-absorbing quality of hyaluronic acid products reduces this wear on the articular cartilage, allowing it to heal. The product itself does not remain in the joint space long after injection, as it lasts only hours or days. The therapeutic benefit, however, can last up to half a year, indicating that there may be some element of
anti-inflammatory action or stimulation of the body’s natural ability to replenish the joint fluid. Because there is no pharmacologic action associated with the treatment, these products are classified as medical devices in the majority of circumstances. In India, however, most HA products are classified as drugs.

Read more and order at Japanese Market Report for Hyaluronic Acid Viscosupplementation